1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. RxSight, Inc.
  6. Summary
    RXST   US78349D1072

RXSIGHT, INC.

(RXST)
  Report
Real-time Estimate Cboe BZX  -  12:20 2022-08-09 pm EDT
14.86 USD   -5.05%
09:16aRXSIGHT : Corporate Presentation
PU
05:57aNeedham Raises RxSight's Price Target to $22 From $19, Maintains Buy Rating
MT
03:42aRxSight Files $200 Million Mixed Shelf, Announces $50 Million At-the-Market Equity Offering
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
14.95(c) 15.07(c) 15.7(c) 15.65(c) 14.95 Last
40 685 44 740 51 771 56 563 45 735 Volume
+1.77% +0.80% +4.18% -0.32% -4.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 45,0 M - -
Net income 2022 -76,1 M - -
Net Debt 2022 24,0 M - -
P/E ratio 2022 -5,69x
Yield 2022 -
Sales 2023 80,9 M - -
Net income 2023 -64,3 M - -
Net Debt 2023 15,0 M - -
P/E ratio 2023 -7,22x
Yield 2023 -
Capitalization 432 M 432 M -
EV / Sales 2022 10,2x
EV / Sales 2023 5,53x
Nbr of Employees 221
Free-Float 78,3%
More Financials
Company
RxSight, Inc. is a commercial-stage medical technology company. The Company is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system), comprised of its RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity... 
More about the company
Ratings of RxSight, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about RXSIGHT, INC.
09:16aRXSIGHT : Corporate Presentation
PU
05:57aNeedham Raises RxSight's Price Target to $22 From $19, Maintains Buy Rating
MT
03:42aRxSight Files $200 Million Mixed Shelf, Announces $50 Million At-the-Market Equity Offe..
MT
08/08RXSIGHT : Files Shelf Registration Statement and Announces $50 Million At-The-Market Equit..
PU
08/08RXSIGHT : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/08RXSIGHT, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhib..
AQ
08/08TRANSCRIPT : RxSight, Inc., Q2 2022 Earnings Call, Aug 08, 2022
CI
08/08RXSIGHT, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/08Earnings Flash (RXST) RXSIGHT Posts Q2 Revenue $11.4M
MT
08/08Earnings Flash (RXST) RXSIGHT Posts Q2 Loss $-0.50
MT
08/08RxSight, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/08RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Marke..
GL
08/08RxSight, Inc. Reports Second Quarter 2022 Financial Results
GL
08/08Rxsight, Inc. Revises Revenue Guidance for the Full Year 2022
CI
07/25RxSight, Inc. to Report Second Quarter 2022 Financial Results on August 8, 2022
GL
More news
News in other languages on RXSIGHT, INC.
03:42aRxSight dépose un prospectus simplifié de 200 millions de dollars et propose une offre ..
08/08Earnings Flash (RXST) RXSIGHT affiche un chiffre d'affaires de 11,4 millions de dollars..
08/08RxSight, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 3..
08/08Rxsight, Inc. révise ses prévisions de revenus pour l'ensemble de l'année 2022
07/11La demande d'information de la FDA n'affectera probablement pas le calendrier de lancem..
More news
Analyst Recommendations on RXSIGHT, INC.
More recommendations
Chart RXSIGHT, INC.
Duration : Period :
RxSight, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RXSIGHT, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 15,65 $
Average target price 20,00 $
Spread / Average Target 27,8%
EPS Revisions
Managers and Directors
Ronald M. Kurtz President, Chief Executive Officer & Director
Shelley B. Thunen Chief Financial Officer
J. Andrew Corley Chairman
Christian A. Sandstedt Director-Optics, Research & Development
Matt Haller Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
RXSIGHT, INC.39.11%430
ABBOTT LABORATORIES-22.37%190 883
MEDTRONIC PLC-9.83%124 341
BECTON, DICKINSON AND COMPANY4.15%73 001
HOYA CORPORATION-15.34%38 786
DEXCOM, INC.-31.91%35 882